Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2010 - 2026)

Cumberland Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $71.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 1.51% year-over-year to $71.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.6 million (down 6.37% YoY) and the FY2025 annual result came in at $76.8 million, up 1.64% from the prior year.
• Liabilities and Shareholders Equity declined to $71.0 million in Q1 2026 per CPIX's latest filing, from $76.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $96.7 million in Q1 2022 and troughed at $65.9 million in Q3 2025.
• A 5-year average of $81.5 million and a median of $81.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity grew 10.02% in 2022, then fell 14.2% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $92.9 million in 2022, then retreated by 12.0% to $81.8 million in 2023, then declined by 7.57% to $75.6 million in 2024, then rose by 1.64% to $76.8 million in 2025, then slipped by 7.59% to $71.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $71.0 million, $76.8 million, and $65.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.